Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2022
Effectiveness of Jiedu granule on gut microbiota in patients with advanced hepatocellular carcinoma: a randomized controlled trial.
Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 5 citations in OpenAlex.
- The role of Traditional Chinese Medicine in the management of liver disease: targeting gut microbiome.Chinese medicine · 2026Review
- Gut microbiota-metabolism-immunity axis: a novel perspective of traditional Chinese medicine in hepatocellular carcinoma treatment.Chinese medicine · 2026Article
- Efficacy and safety of Yangxiao Fukang granule in the treatment of stage Ⅲ hepatitis B related liver cancer: study protocol for a randomized controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Research Hotspots of Traditional Chinese Medicine for Liver Cancer in the Future Directions: A Bibliometric Analysis.Journal of hepatocellular carcinoma · 2025Article
- Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance.Frontiers in microbiology · 2025Review
- The protective effect and antitumor activity ofFrontiers in pharmacology · 2023Article
- G. lucidum triterpenes restores intestinal flora balance in non-hepatitis B virus-related hepatocellular carcinoma: evidence of 16S rRNA sequencing and network pharmacology analysis.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo observe whether Jiedu granule (, JDG) modulates the composition of the gut microbiota during advanced hepatocellular carcinoma (HCC).
methodsA randomized controlled trial was conducted. Sixty-two advanced HCC participants were randomly allocated to receive JDG or placebo. The median overall survival (OS) times of patients and the variation of relative abundance of bacteria over time were used as main outcome measures.
resultsPatients who received JDG demonstrated significantly longer median OS times compared with the placebo group. Pyrosequencing of the V3 regions of 16S rRNA genes revealed a dose dependent deviation of gut microbiota in response to JDG treatment. Redundancy analysis identified and Peptostre-ptococcaceae which related to the onset of liver cancer disappeared after 1-month and 2-month JDG treatment, while in control group, no significant changes of these two bacteria were found. The variation tendency of relative abundance of (essential in immunoblocking therapy of tumor) in JDG group was not obvious while in control group, it was decreased significantly with time. The relative abundance of (correlated with the occurrence of liver cancer) was increased in JDG group and was decreased in control group over time.
conclusionChanges in the gut microbiota may be associated with the efficiency of JDG on survival period of advanced HCC patients. Trial registration：Chinese Clinical TRIAL Registry ChiCTR-OOC-16008002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.